CG Oncology, Inc. (CGON) Stock Statistics & Valuation Metrics

CG Oncology, Inc. has a market cap or net worth of $1.36B. The enterprise value is $1.44B.

CG Oncology, Inc. has 76.22M shares outstanding. The number of shares has decreased by -2.65% in one year.

CG Oncology, Inc.’s return on equity (ROE) is -0.12 and return on invested capital (ROIC) is -15.63%.

The current PE Ratio of CG Oncology, Inc. is -20.36. CG Oncology, Inc.’s PEG ratio is 0.22.

In the last 12 months, CG Oncology, Inc. had revenue of $684.00K and earned -$72.36M in profits. Earnings per share was -$1.18.

In the last 12 months, operating cash flow was -$74.11M and capital expenditures -$25.00K, giving a free cash flow of -$74.14M billion.

CG Oncology, Inc. pays an annual dividend of , resulting in a dividend yield of

CG Oncology, Inc. upcoming earnings date is May 8, 2025, Before Open.

CG Oncology, Inc. as a current ratio of 35.30, with Debt / Equity ratio of <0.01

In the past 12 months, CG Oncology, Inc. has paid $0.00 in taxes.

CG Oncology, Inc. EV to EBITDA ratio is -13.39, with an EV/FCF ratio of -19.45.

CG Oncology, Inc. has $540.71M in cash and marketable securities with $296.00K in debt, giving a net cash position of -$540.41M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for CG Oncology, Inc. is $68.60, which is 11.43% higher than the current price. The consensus rating is Strong Buy